RxDoctor Payments DataLook up a doctor →

Christopher Skelley, MD

Internal Medicine · Bryant, ARNPI 1215905575

Payments from drug & device makers

$9,076in general payments, 2019–2025

Across 620 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Amgen$951
  • Pfizer$450
  • Boehringer Ingelheim$449
  • Lilly USA, LLC$444
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,076 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$173,101
Medicare patients
392
Services billed
2,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide186$191,570
OzempicSemaglutide130$127,338
JardianceEmpagliflozin87$75,887
EliquisApixaban72$62,170
TrulicityDulaglutide55$59,629
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$38,792
LinzessLinaclotide47$35,701
FarxigaDapagliflozin Propanediol41$33,078
JanuviaSitagliptin Phosphate26$31,670
OxycontinOxycodone Hcl27$19,723
CreonLipase/Protease/Amylase16$19,330
XareltoRivaroxaban25$15,768
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$15,523
Tresiba Flextouch U-100Insulin Degludec13$13,181
Emgality PenGalcanezumab-Gnlm15$10,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$444$251,199241 claims
Novo NordiskOzempic$436$127,338130 claims
Boehringer IngelheimJardiance$449$75,88787 claims
PfizerEliquis$450$62,17072 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,162$57,00090 claims
AbbVieLinzess, Creon$1,530$55,03163 claims
GSKTrelegy Ellipta, Breo Ellipta$212$44,81860 claims
MerckJanuvia$251$31,67026 claims
Johnson & JohnsonXarelto$107$15,76825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Bryant

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →